# Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

> **NCT01406470** · PHASE3 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 45 (actual)

## Conditions studied

- Immunologic Deficiency Syndrome

## Interventions

- **DRUG:** Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™

## Key facts

- **NCT ID:** NCT01406470
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01406470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01406470, "Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01406470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*